Publications

2.       Silver SV, Popovics P$. The Multifaceted Role of Osteopontin in Prostate Pathologies. Biomedicines. 2023 October; 11(11):2895.

3.       Popovics P#, Skalitzky KO, Schroeder E, Jain A, Silver SV, Van Fritz F, Uchtmann KS, Vezina CM, Ricke WA#. Steroid hormone imbalance drives macrophage infiltration and Spp1/osteopontin(+) foam cell differentiation in the prostate. J Pathol. 2023 Jun;260(2):177-189. doi: 10.1002/path.6074. Epub 2023 Apr 4. PubMed PMID: 36825524; PubMed Central PMCID: PMC10231633.

4.       Popovics P, Penniston KL. Current research and future directions in non-malignant urologic research - proceedings of the annual CAIRIBU meeting. Am J Clin Exp Urol. 2022;10(6):449-461. eCollection 2022. PubMed PMID: 36636691; PubMed Central PMCID: PMC9831912.

5.       Cai R, Zhang X, Wang H, Cui T, Halmos G, Sha W, He J, Popovics P, Vidaurre I, Zhang C, Mirsaeidi M, Schally AV. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides. 2022 Apr;150:170716. doi: 10.1016/j.peptides.2021.170716. Epub 2021 Dec 21. PubMed PMID: 34952135.

6.       Popovics P, Jain A, Skalitzky KO, Schroeder E, Ruetten H, Cadena M, Uchtmann KS, Vezina CM, Ricke WA. Osteopontin Deficiency Ameliorates Prostatic Fibrosis and Inflammation. Int J Mol Sci. 2021 Nov 18;22(22). doi: 10.3390/ijms222212461. PubMed PMID: 34830342; PubMed Central PMCID: PMC8617904.

7.       Nanda JS, Awadallah WN, Kohrt SE, Popovics P, Cates JMM, Mirosevich J, Clark PE, Giannico GA, Grabowska MM. Increased nuclear factor I/B expression in prostate cancer correlates with AR expression. Prostate. 2020 Sep;80(13):1058-1070. doi: 10.1002/pros.24019. Epub 2020 Jul 21. PubMed PMID: 32692871; PubMed Central PMCID: PMC7434711.

8.       Popovics P#, Awadallah WN, Kohrt SE, Case TC, Miller NL, Ricke EA, Huang W, Ramirez-Solano M, Liu Q, Vezina CM, Matusik RJ, Ricke WA, Grabowska MM. Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia. Prostate. 2020 Jul;80(10):731-741. doi: 10.1002/pros.23986. Epub 2020 May 1. PubMed PMID: 32356572; PubMed Central PMCID: PMC7485377.

9.       Schally AV, Wang H, He J, Cai R, Sha W, Popovics P, Perez R, Vidaurre I, Zhang X. Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12028-12033. doi: 10.1073/pnas.1813375115. Epub 2018 Oct 29. PubMed PMID: 30373845; PubMed Central PMCID: PMC6255156.

10.       Popovics P$, Cai R, Sha W, Rick FG, Schally AV. Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis. Prostate. 2018 Sep;78(13):970-980. doi: 10.1002/pros.23655. Epub 2018 May 21. PubMed PMID: 29786867.

11.   Jimenez JJ, DelCanto GM, Popovics P, Perez A, Vila Granda A, Vidaurre I, Cai RZ, Rick FG, Swords RT, Schally AV. A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. Br J Haematol. 2018 May;181(4):476-485. doi: 12.1111/bjh.15207. Epub 2018 Apr 16. PubMed PMID: 29663325.

13.   Zarandi M, Cai R, Kovacs M, Popovics P, Szalontay L, Cui T, Sha W, Jaszberenyi M, Varga J, Zhang X, Block NL, Rick FG, Halmos G, Schally AV. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides. 2017 Mar;89:60-70. doi: 10.1016/j.peptides.2017.01.009. Epub 2017 Jan 24. PubMed PMID: 28130121.

14.   Popovics P, Schally AV, Salgueiro L, Kovacs K, Rick FG. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells. Proc Natl Acad Sci U S A. 2017 Feb 7;114(6):1359-1364. doi: 10.1073/pnas.1620884114. Epub 2017 Jan 25. PubMed PMID: 28123062; PubMed Central PMCID: PMC5307470.

15.   Arastoo M, Hacker C, Popovics P, Lucocq JM, Stewart AJ. Erratum to: Phospholipase C-η2 interacts with nuclear and cytoplasmic LIMK-1 during retinoic acid-stimulated neurite growth. Histochem Cell Biol. 2016 Jun;145(6):681. doi: 10.1007/s00418-016-1418-7. PubMed PMID: 26873005; PubMed Central PMCID: PMC4969822.

16.   Arastoo M, Hacker C, Popovics P, Lucocq JM, Stewart AJ. Phospholipase C-η2 interacts with nuclear and cytoplasmic LIMK-1 during retinoic acid-stimulated neurite growth. Histochem Cell Biol. 2016 Feb;145(2):163-73. doi: 10.1007/s00418-015-1390-7. Epub 2015 Dec 15. PubMed PMID: 26671787; PubMed Central PMCID: PMC4735258.

17.   Zhang X, Cui T, He J, Wang H, Cai R, Popovics P, Vidaurre I, Sha W, Schmid J, Ludwig B, Block NL, Bornstein SR, Schally AV. Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13651-6. doi: 10.1073/pnas.1518540112. Epub 2015 Oct 16. PubMed PMID: 26474831; PubMed Central PMCID: PMC4640729.

18.   Popovics P*, Frigo DE*, Schally AV, Rick FG. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. Expert Opin Ther Targets. 2015 May;19(5):617-32. doi: 10.1517/14728222.2015.1005603. Epub 2015 Jan 20. Review. PubMed PMID: 25600663.

19.   Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. doi: 10.18632/oncotarget.3303. PubMed PMID: 25797248; PubMed Central PMCID: PMC4496393.

20.   Perez R, Schally AV, Popovics P, Cai R, Sha W, Rincon R, Rick FG. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study. Oncoscience. 2014;1(10):665-73. doi: 10.18632/oncoscience.92. eCollection 2014. PubMed PMID: 25593995; PubMed Central PMCID: PMC4278278.

21.   Popovics P, Schally AV, Szalontay L, Block NL, Rick FG. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget. 2014 Jun 30;5(12):4567-78. doi: 10.18632/oncotarget.2146. PubMed PMID: 24994120; PubMed Central PMCID: PMC4147346.

22.   Popovics P, Lu J, Nadia Kamil L, Morgan K, Millar RP, Schmid R, Blindauer CA, Stewart AJ. A canonical EF-loop directs Ca(2+) -sensitivity in phospholipase C-η2. J Cell Biochem. 2014 Mar;115(3):557-65. doi: 10.1002/jcb.24690. PubMed PMID: 24123053.

23.   Cai R, Schally AV, Cui T, Szalontay L, Halmos G, Sha W, Kovacs M, Jaszberenyi M, He J, Rick FG, Popovics P, Kanashiro-Takeuchi R, Hare JM, Block NL, Zarandi M. Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides. 2014 Feb;52:104-12. doi: 10.1016/j.peptides.2013.12.010. Epub 2013 Dec 25. PubMed PMID: 24373935; PubMed Central PMCID: PMC4745889.

24.   Jaszberenyi M, Rick FG, Popovics P, Block NL, Zarandi M, Cai RZ, Vidaurre I, Szalontay L, Jayakumar AR, Schally AV. Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):781-6. doi: 10.1073/pnas.1322622111. Epub 2013 Dec 30. PubMed PMID: 24379381; PubMed Central PMCID: PMC3896165.

25.   Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle. 2014;13(17):2790-7. doi: 10.4161/15384101.2015.945879. PubMed PMID: 25486366; PubMed Central PMCID: PMC4615138.

26.   Kanczkowski W, Alexaki VI, Tran N, Großklaus S, Zacharowski K, Martinez A, Popovics P, Block NL, Chavakis T, Schally AV, Bornstein SR. Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14801-6. doi: 10.1073/pnas.1313945110. Epub 2013 Aug 19. PubMed PMID: 23959899; PubMed Central PMCID: PMC3767499.

27.   Popovics P, Gray A, Arastoo M, Finelli DK, Tan AJ, Stewart AJ. Phospholipase C-η2 is required for retinoic acid-stimulated neurite growth. J Neurochem. 2013 Mar;124(5):632-44. doi: 10.1111/jnc.12122. Epub 2013 Jan 8. PubMed PMID: 23237262.

28.   Popovics P, Stewart AJ. Putative roles for phospholipase Cη enzymes in neuronal Ca2+ signal modulation. Biochem Soc Trans. 2012 Feb;40(1):282-6. doi: 10.1042/BST20110622. Review. PubMed PMID: 22260706.

29.   Popovics P, Stewart AJ. Phospholipase C-η activity may contribute to Alzheimer's disease-associated calciumopathy. J Alzheimers Dis. 2012;30(4):737-44. doi: 10.3233/JAD-2012-120241. Review. PubMed PMID: 22475800.

30.   Popovics P, Beswick W, Guild SB, Cramb G, Morgan K, Millar RP, Stewart AJ. Phospholipase C-η2 is activated by elevated intracellular Ca(2+) levels. Cell Signal. 2011 Nov;23(11):1777-84. doi: 10.1016/j.cellsig.2011.06.012. Epub 2011 Jun 29. PubMed PMID: 21740965.

31.   Popovics P, Rekasi Z, Stewart AJ, Kovacs M. Regulation of pituitary inhibin/activin subunits and follistatin gene expression by GnRH in female rats. J Endocrinol. 2011 Jul;210(1):71-9. doi: 10.1530/JOE-10-0485. Epub 2011 Apr 13. PubMed PMID: 21490134.

32.   Popovics P, Stewart AJ. GPR39: a Zn(2+)-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life Sci. 2011 Jan;68(1):85-95. doi: 10.1007/s00018-010-0517-1. Epub 2010 Sep 2. Review. PubMed PMID: 20812023.


 

* Co-first author

# Co-corresponding author

$ Corresponding author